S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:MRTX

Mirati Therapeutics - MRTX Stock Forecast, Price & News

$71.52
-21.23 (-22.89%)
(As of 12/6/2022 05:33 PM ET)
Add
Compare
Today's Range
$70.44
$80.30
50-Day Range
$59.44
$98.62
52-Week Range
$32.96
$154.17
Volume
4.16 million shs
Average Volume
1.07 million shs
Market Capitalization
$4.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.64

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
54.1% Upside
$110.64 Price Target
Short Interest
Bearish
14.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
0.18mentions of Mirati Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$7.08 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($13.44) to ($12.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

533rd out of 1,023 stocks

Pharmaceutical Preparations Industry

245th out of 501 stocks

MRTX stock logo

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Stock News Headlines

Why Shares of Mirati Therapeutics Fell Tuesday
Mirati Therapeutics: Poised For Takeoff
Cancer Drugmaker Mirati Draws Fresh Takeover Interest
Mirati Therapeutics Q3 2022 Earnings Preview
What 4 Analyst Ratings Have To Say About Mirati Therapeutics
4 Analysts Have This to Say About Mirati Therapeutics
Amgen’s new cancer drug faces questions about competition
See More Headlines
Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Company Calendar

Last Earnings
11/08/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
413
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$110.64
High Stock Price Forecast
$188.00
Low Stock Price Forecast
$72.00
Forecasted Upside/Downside
+54.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

Net Income
$-581,780,000.00
Net Margins
-6,253.81%
Pretax Margin
-6,251.66%

Debt

Sales & Book Value

Annual Sales
$72.09 million
Book Value
$25.24 per share

Miscellaneous

Free Float
55,589,000
Market Cap
$4.12 billion
Optionable
Optionable
Beta
0.88

Key Executives

  • Mr. David D. Meek (Age 59)
    CEO & Director
    Comp: $974.53k
  • Dr. Charles M. Baum M.D.Dr. Charles M. Baum M.D. (Age 64)
    Ph.D., Founder, Pres, Head of R&D and Director
    Comp: $1.11M
  • Dr. James G. Christensen Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $784.42k
  • Mr. Benjamin J. Hickey M.B.A.Mr. Benjamin J. Hickey M.B.A. (Age 47)
    Chief Commercial Officer
    Comp: $769.03k
  • Ms. Laurie D. Stelzer (Age 54)
    Chief Financial Officer
  • Ms. Reena R. Desai
    Chief Legal Officer & Corp. Sec.
  • Mr. Michael E. Paolucci (Age 62)
    Chief People Officer
  • Dr. Kelly Covello Ph.D.
    VP & Head of Medical Affairs
  • Mr. Ryan Asay
    VP & Head of Corp. Affairs













MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRTX shares.
View MRTX analyst ratings
or view top-rated stocks.

What is Mirati Therapeutics' stock price forecast for 2023?

13 Wall Street research analysts have issued 12 month target prices for Mirati Therapeutics' stock. Their MRTX share price forecasts range from $72.00 to $188.00. On average, they expect the company's stock price to reach $110.64 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for MRTX
or view top-rated stocks among Wall Street analysts.

How have MRTX shares performed in 2022?

Mirati Therapeutics' stock was trading at $146.69 at the beginning of 2022. Since then, MRTX stock has decreased by 36.8% and is now trading at $92.75.
View the best growth stocks for 2022 here
.

When is Mirati Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our MRTX earnings forecast
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($1.55) earnings per share for the quarter, beating the consensus estimate of ($2.87) by $1.32. The biotechnology company had revenue of $71.79 million for the quarter, compared to analyst estimates of $1.41 million. Mirati Therapeutics had a negative trailing twelve-month return on equity of 60.40% and a negative net margin of 6,253.81%. The firm's revenue was up 528.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.96) earnings per share.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.21%), Perceptive Advisors LLC (4.84%), BlackRock Inc. (4.22%), Armistice Capital LLC (3.30%), State Street Corp (2.73%) and Price T Rowe Associates Inc. MD (1.98%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Isan Chen, Jamie Christensen, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends
.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $92.75.

How much money does Mirati Therapeutics make?

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $5.34 billion and generates $72.09 million in revenue each year. The biotechnology company earns $-581,780,000.00 in net income (profit) each year or ($13.39) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

The company employs 413 workers across the globe.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 12/6/2022 by MarketBeat.com Staff